<DOC>
	<DOC>NCT00243347</DOC>
	<brief_summary>This study is to examine the effects on tumors of AZD2171, in the treatment of NSCLC or HNC. The safety and tolerability of AZD2171 will also be studied.</brief_summary>
	<brief_title>The Effects of AZD2171 in Patients With Non-Small Cell Lung Cancer or Head &amp; Neck Cancer</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Head and Neck Neoplasms</mesh_term>
	<mesh_term>Cediranib</mesh_term>
	<criteria>Histologically or cytologically confirmed head and neck cancer (HNC) or unresectable stage IIIb or IV nonsmall cell lung cancer (NSCLC) At least one lesion able to be used for tumor biopsy and to be measured by FDGPET Scan Considered suitable for treatment of NSCLC with no prior biological or immunological therapy for disease Or considered suitable for treatment for metastatic or recurrent HNC with no prior biological or immunological therapy for disease NSCLC: Have received more than 2 previous chemotherapy regimens or have received the last chemotherapy or radiotherapy within 28 days of first dose of AZD2171 HNC: Previous chemotherapy or radiotherapy if received 28 days of first dose of AZD2171 Untreatable, unstable brain or meningeal metastases. Abnormal liver and kidney blood chemistries History of poorly controlled hypertension with resting blood pressure of &gt;150/100 Recent (&lt; 14 days) major surgery or a surgical incision not fully healed Diabetes patients with type I insulin dependent diabetes or poorly controlled type II Significant hemorrhage or hemoptysis Presence of necrotic/hemorrhagic tumor or metastases</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2013</verification_date>
	<keyword>RECENTIN</keyword>
</DOC>